Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK)
20 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|45||2016||Co-Chairman of the Board, Executive Director|
|48||2016||Co-Chairman of the Board|
|48||2016||President, Chief Executive Officer, Executive Director|
|46||2016||Chief Financial Officer, Senior Vice President, Chief Accounting Officer|
|42||Senior Vice President|
- China, Hong Kong stocks fall on soft exports data
- BRIEF-Shanghai Fosun Pharmaceutical Group to pay cash dividend of 3.8 yuan (pre-tax) for every 10 shares
- BRIEF-Shanghai Fosun Pharmaceutical Group Says Guo Guangchang Resigned As Non-Executive Director
- BRIEF-Shanghai Fosun Pharmaceutical's 2017 Net Profit Up, To Invest Up To 1 Bln Yuan In Project
- BRIEF-Dova Pharmaceuticals Signs Distribution Agreement With Fosun Pharma For Mainland China And Hong Kong